Metabolic Diversity in Tumors Assessed by 18F-FDG PET/CT as a Prognostic Indicator in Diffuse Large B-Cell Lymphoma
-
By
-
Wenchong Xin
-
Fei Wang
-
Luo Lu
-
Haoyu Zang
-
Bai He
-
Weiying Gu
-
Yuetao Wang
-
November 24, 2025
-
Clinical Scorecard: Metabolic Diversity in Tumors Assessed by 18F-FDG PET/CT as a Prognostic Indicator in Diffuse Large B-Cell Lymphoma
At a Glance
| Category | Detail |
|---|
| Condition | Diffuse Large B-Cell Lymphoma (DLBCL) |
| Key Mechanisms | Assessment of tumor metabolic heterogeneity using 18F-FDG PET/CT. |
| Target Population | Patients diagnosed with DLBCL undergoing R-CHOP or R-CHOP-like treatment. |
| Care Setting | Oncology clinics and hospitals performing PET/CT imaging. |
Key Highlights
- DLBCL is the most common aggressive non-Hodgkin lymphoma subtype.
- R-CHOP treatment improves prognosis in nearly 90% of limited-stage patients.
- Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are key PET metrics.
- Tumor heterogeneity is linked to treatment failure and disease progression.
- AUC-CSH method may enhance prognostic stratification in DLBCL.
Guideline-Based Recommendations
Diagnosis
- Histopathological diagnosis of DLBCL.
- Baseline 18F-FDG PET/CT scan is essential.
Management
- First-line treatment with R-CHOP or R-CHOP-like regimens.
Monitoring & Follow-up
- Utilize 18F-FDG PET/CT for assessing disease burden and treatment response.
Risks
- Poor outcomes for patients failing R-CHOP, with a median OS of 6 months.
Patient & Prescribing Data
297 individuals with DLBCL treated at the Third Affiliated Hospital of Soochow University.
Timely identification of relapsed/refractory patients is critical for optimizing treatment.
Clinical Best Practices
- Incorporate metabolic heterogeneity assessment in prognostic models.
- Use AUC-CSH method for non-invasive tumor characterization.
References
